UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287	7			
Estimated average burden					
ours per response					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
1. Name and Address of Reporting Person * Miller Robert E				2. Issuer Name and Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 03/08/2017						X Officer (give title below) Other (specify below) Chief Financial Officer					
(Street) PETALUMA, CA 94954			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							ired, Disposed of, or Beneficially Owned				
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		f Code (Instr. 8)		4. Securities Acquire (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			6. Ownership Form: Direct (D)	Beneficial Ownership	
					(Code	V	Amoun	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common value per	Stock, \$0. share	0001 par	03/08/2017			P		250	A	\$ 6.81	6,964			I	See Note (1)
Common value per	Stock, \$0.	0001 par	03/08/2017			P		750	A	\$ 6.97	7,714			I	See Note (1)
Common value per	Stock, \$0.	0001 par									15,964			D	
Reminder: indirectly.	Report on a	separate line f	for each class of secu	rities beneficially	owne	ed dire	ctly o	r							
mancetry.							cont	ained ii	n this fo	orm ar	e not req	ction of ir uired to re d OMB cor	spond un	less	EC 1474 (9- 02)
				Derivative Securi 2.g., puts, calls, w								I			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		on 3A. Deemed Execution Day (Year) any	4.	on of		and Expiration Date (Month/Day/Year) S (I) 4		7. T Ame Und Seco	itle and ount of lerlying urities tr. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Owners Form of Derivate Security Direct (or Indire	Ownership (Instr. 4)	
				Code V	(A)	(D)	Date Exe		Expiration Date	On Title	Amount or Number of Shares				
Repor	ting O	wners													

Donatha Oman Nama (Addana	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Miller Robert E C/O SONOMA PHARMACEUTICALS, INC. 1129 N. MCDOWELL BLVD. PETALUMA, CA 94954			Chief Financial Officer				

Signatures

/s/ Robert E. Miller	03/09/2017
**Signature of Reporting	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These shares are owned by Mr. Miller as trustee for The Miller 2005 Grandchildren's Trust, for which Mr. Miller and his wife, Margaret I. Miller, are the trustees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.